AG992

LRRK2 Control Peptide

• UNSPSC-Code: 12352202
• eCl@ss: 32160405
• NACRES: NA.32

Eigenschaften

• Konzentration: 1 mg/mL
• Qualitätsniveau: 300
• Methode(n): inhibition assay: suitable
• UniProt-Hinterlegungsnummer: Q5S007
• Angaben zum Gen: rat ... LRRK2(300160)

Beschreibung

Allgemeine Beschreibung

FUNCTION: SwissProt: Q5S007 # Probable protein kinase whose role is not yet known. May play a role in the phosphorylation of proteins central to Parkinson disease. May also have GTPase activity.
SIZE: 2527 amino acids; 286058 Da
SUBUNIT: Interacts with PARK2.
SUBCELLULAR LOCATION: Cytoplasm. Membrane; Peripheral membrane protein. Note=Localized in the cytoplasm and associated with cellular membrane structures. Associates with the mitochondrial outer membrane.
TISSUE SPECIFICITY: Expressed throughout the adult brain, but at a lower level than in heart and liver. Also expressed in placenta, lung, skeletal muscle, kidney and pancreas. In the brain, expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas.
DISEASE: SwissProt: Q5S007 # Defects in LRRK2 are the cause of Parkinson disease 8 (PARK8) [MIM:607060, 168600]. Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK8 is an autosomal-dominant late- onset parkinsonism, characterized by onset from 50 to 65 years, with slow progression and relatively benign course.
SIMILARITY: SwissProt: Q5S007 ## Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. & Contains 16 LRR (leucine-rich) repeats. & Contains 1 Miro domain. & Contains 1 protein kinase domain.

Anwendung

Antibody blocking (AB9682)

Optimal working concentration must be determined by the end user.

Physikalische Form

Liquid.

Lagerung und Haltbarkeit

Store at -20°C in undiluted aliquots for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles.

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.